Skip to main content

Table 3 Reasons for study withdrawal

From: Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer

Reason for study withdrawal, n (%)

H

N = 25

AE/intercurrent illness

1 (4.0)

Insufficient therapeutic responsea

6 (24.0)

Switch to commercially available H treatment

2 (8.0)

Refusal of treatment

1 (4.0)

Other

15 (60.0)

 Study completion/closure

5 (20.0)

 Sponsor request

4 (16.0)

 Investigator decision

3 (12.0)

 Switch to H SC

2 (8.0)

 Treatment discontinued until further disease progression

1 (4.0)

  1. aIncludes patients who experienced disease progression
  2. Abbreviations: AE adverse event, H trastuzumab (Herceptin®), H SC subcutaneous trastuzumab (Herceptin® SC)